(NASDAQ: ABCL) Abcellera Biologics's forecast annual revenue growth rate of -15.34% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Abcellera Biologics's revenue in 2026 is $66,173,000.On average, 11 Wall Street analysts forecast ABCL's revenue for 2026 to be $9,888,526,390, with the lowest ABCL revenue forecast at $7,756,963,478, and the highest ABCL revenue forecast at $12,446,279,239. On average, 10 Wall Street analysts forecast ABCL's revenue for 2027 to be $10,544,981,539, with the lowest ABCL revenue forecast at $8,173,035,238, and the highest ABCL revenue forecast at $13,727,608,556.
In 2028, ABCL is forecast to generate $12,593,146,132 in revenue, with the lowest revenue forecast at $8,175,488,129 and the highest revenue forecast at $15,730,088,040.